Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 2

338 - Factors affecting disease free survival and overall survival in locally advanced breast cancer patients presented to Alexandria Clinical Oncology Department (ACOD 10 years experience)


20 Dec 2015


Poster presentation 2


hanady Hegazy


Annals of Oncology (2015) 26 (suppl_9): 16-33. 10.1093/annonc/mdv519


H.M. Hegazy1, A. Omar1, A. El Enbaby2, A. Gewel2

Author affiliations

  • 1 Clinical Oncology And Nuclear Medicine, University of Alexandria Faculty of Medicine, 21321 - Alexandria/EG
  • 2 Clinical Oncology And Nuclear Medicine, University of Alexandria Faculty of Medicine, Alexandria/EG


Abstract 338


This study aimed at evaluation of the different prognostic factors that might have impact on DFS and OS in patients with locally advanced breast cancer seen in Alexandria Clinical Oncology department.


Study was conducted in ACOD for 780 patients with locally advanced breast cancer presented in the period from January 2003 to December 2012. Patients' files were analyzed and data was collected in a predesigned Excel sheet and the SPSS version 21 was used to analyze the data. The 5 years DFS and OS were calculated by Kaplan Meier method and were correlated with age, family history, tumor size, histological grade, hormonal receptor status and HER2 status and the different treatment lines used.


Of the 780 patients with locally advanced breast cancer, the mean age was 50 years old and 4.2% had positive family history. 69.4% of patients were grade GII, 77.1% with tumor size of T2 (2-5cm), ER and PR positive in 91.2% and Her2 positive in 15.6% of patients. Regarding the treatment, 95% of patients underwent MRM, 92.3% received adjuvant chemotherapy and 7.7% received neoadjuvant chemotherapy. Adjuvant radiotherapy was received in 98.5% of patients while 75.8% received hormonal treatment. The 5 years DFS and OS were 65.8% and 72% respectively. Family history, tumor grade and hormonal treatment had a significant impact on both DFS and OS.Tumor size, Her2 status and radiotherapy significantly affected the DFS while surgery affected the OS significantly. The neoadjuvant chemotherapy achieved better DFS and OS than adjuvant chemotherapy but the relation was statistically insignificant.


The age, family history, histological grade, tumor size, hormonal receptors and HER2 status and treatment used are important factors that affect the DFS and OS in ACOD locally advanced breast cancer patients either significantly or not. Further randomized studies with large number of patients should be conducted for evaluation of these factors impact on survival as this will affect greatly our consensus of treatment for those patients.

Clinical trial identification


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings